People · Operator
Named in public records as an officer, director or promoter · active 2010–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Therabron Therapeutics, Inc. | — | Biotechnology | Series A | $15.6M | $84.1M | 2010 |
Aprile Pilon-Clayton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aprile Pilon-Clayton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Vinzenz Ploerer | 1 | 4 |
| Christine Copple | 1 | 2 |
| Thomas M. Miller | 1 | 2 |
| Vinzenz M. Ploerer | 1 | 1 |
| Aprile L. Pilon-Clayton | 1 | 1 |
| Christine M. Copple | 1 | 1 |
| Blanche M. Johnson | 1 | 1 |
| Todd M Brady | 1 | 1 |
| Eric M Richman | 1 | 1 |
| Jeffrey Zell | 1 | 1 |
| Linda M Chang | 1 | 1 |
| Blanche Johnson | 1 | 1 |
| Jeffrey M. Zell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.